Arthroscopy of the knee is performed regularly on a day-case basis. Intra-articular bupivacaine produces transient analgesia and reports of analgesia using intra-articular morphine have produced conflicting results. Non-steroidal anti-inflammatory drugs given systemically can provide effective analgesia for this procedure. In this study we attempted to determine if intra-articular tenoxicam provided useful analgesia after day-case arthroscopy. Sixty three ASA I-II patients were allocated randomly to one of three groups to receive 40 ml of a solution containing 0.9% saline (group Pla), 0.25% bupivacaine (group Bup) or tenoxicam 20 mg (group Ten). The injection was made into the knee joint at the end of surgery, 10 min before tourniquet deflation. Verbal rating and visual analogue pain scores (at rest and on knee flexion), use of analgesia, mobilization and disturbance by pain at home were recorded for the next 48 h. There were no differences between pain scores in any of the three groups when tested at rest or on movement. Less analgesia was used in the first 24 h by patients in the tenoxicam group but the difference in time to first analgesia was not statistically significant. Side effects and disturbance by pain were similar in all groups. The use of intra-articular tenoxicam 20 mg at the end of arthroscopy reduced oral analgesic requirements during the first day after operation but did not alter patients' perception of pain. (Br.
Arthroscopy of the knee is associated with postoperative pain that may require systemic analgesia and can delay hospital discharge. It is common to undertake the procedure as a day case. Efforts have, been made to determine the best method of pain relief, to maximize analgesia and minimize side effects. Analgesic approaches include systemic opioids or systemic non-steroidal anti-inflammatory drugs (NSAID). 1 The use of locally administered analgesia is appealing and intra-articular local anaesthetics 2 3 and more recently intra-articular opioids 4 have been reported to be effective.
In contrast with opioids, NSAID have principal effects peripherally and therefore local application to the site of injury should produce analgesia while minimizing systemic side effects. 5 We set out to determine if there is a role for intra-articular tenoxicam (Mobiflex) in the prevention of pain after knee arthroscopy.
Patients and methods
Before starting the study the local Ethics Committee gave approval and the Medicines Control Agency provided an exemption to the product licence for tenoxicam. We studied 63 patients undergoing elective knee arthroscopy. All patients gave informed, written consent and were advised that the intraarticular use of the trial drugs was a non-licensed method of administration.
Patients receiving NSAID in the previous 7 days, who were allergic to NSAID or local anaesthetics, who had contraindications to NSAID or local anaesthetics, those who were or might be pregnant, those aged less than 16 yr or more than 75 yr and those known to have osteoarthritis of the knee were excluded. We also planned to exclude those patients found to have osteoarthritis at the time of surgery, although none was found.
Instruction was given on using a 100-mm visual analogue scale (VAS) with 0 mm labelled "no pain" and 100 mm "worst pain imaginable". Instruction was also given on completing a pain verbal rating scale (VRS): ratings were "no pain", "mild pain", "moderate pain" and "severe pain". Preoperative pain scores at rest and on movement were recorded.
No premedication was given. A standardized general anaesthetic was administered. A sleep dose of propofol and fentanyl 1 g kg 91 was followed by maintenance with isoflurane and 66% nitrous oxide in oxygen. Patients breathed spontaneously via a laryngeal mask airway and a circle breathing system. Monitoring included inspired oxygen, electrocardiograph, non-invasive arterial pressure, pulse oximetry and capnography.
Patients were allocated randomly (with sealed envelopes) to one of three groups. Group Bup received 0.25% bupivacaine 40 ml into the knee joint; group Ten received a 40-ml injection of 0.9% saline containing tenoxicam 20 mg; and group Pla received a placebo injection of 40 ml of 0.9% saline. These injections were administered into the knee joint, by the surgeon, 10 min before the limb tourniquet was deflated. VAS and VRS scores were recorded 30, 60, 120 and 180 min after tourniquet deflation and on another five specified occasions over the first 48 h after surgery. All VAS and VRS scores were recorded "at rest" and "on movement" (knee flexion). Patients recorded their analgesic use over this time.
Additional analgesia was prescribed as coproxamol (dextropropoxyphene hydrochloride 32.5 mg and paracetamol 325 mg) as required, up to eight tablets a day. A supply of co-proxamol was given to the patient to take home and patients were requested not to consume any other analgesics. Morphine 0.15 mg kg 91 and co-proxamol were available on request while in hospital.
Age, weight, sex, preoperative pain scores, tourniquet times, surgical grade and surgical procedure were analysed (by one-way ANOVA and chi-square where appropriate) to exclude important differences between groups. Pain scores and analgesic requirements during the first 48 h were compared between groups using repeated measures ANOVA. The time to first analgesic use was studied by Kaplan-Meier survival analysis. Results were considered statistically significant when P:0.05. The statistical packages used were MS Excel (version 5.0) and SPSS for Windows (release 6.1) both running in MS Windows (release 3.1).
Previous studies suggested an SD of up to 20 mm for VAS scores after knee arthroscopy in patients receiving intra-articular analgesia. 6 With 20 patients in each group the study was designed to have 80% power to detect an 18-mm difference in VAS score at a 5% level of significance. We considered that differences of less than 18 mm would not be clinically significant.
Results
Patient characteristics were similar in all groups with the exception that patients in group Bup were younger than those in the other groups. Indications for surgery, distribution of diagnostic and interventional arthroscopy, duration of surgery and seniority of the surgeons did not differ significantly between groups (table 1) . There were no significant differences in preoperative pain scores between groups. All patients completed the study. All questionnaires were returned but in some cases not all pain scores were completed. There was no significant difference between groups in either VAS or VRS scores at any time, either at rest or during movement ( figs 1-4) .
The same number of patients (3) in each group received morphine. Time to first analgesia was longest in group Ten but the differences between groups was not significant and this was confirmed by survival analysis (fig. 5 ). All patients in group Pla requested analgesia within 6 h after surgery and in group Bup within 7 h. Four patients in group Ten required no analgesia for more than 8 h.
The number of co-proxamol tablets consumed in the first 24 h was significantly less in group Ten than in the other groups (P:0.05). The number of tablets taken in the first 48 h was less in group Ten than in the two other groups but this was not statistically significant (table 2) . At home five patients took all the analgesia available to them in the first 48 h (16 tablets) while 10 patients took none.
There were no differences in the number of patients disturbed by pain on the first or second night after operation, or in reported adverse effects (table 3) . All groups were similar in the time taken to mobilize. Mobilization was supervised by a physiotherapist who saw patients at least 2 h after operation. Most patients were mobile on the first attempt and 57 of the 60 patients were discharged during the same half-day. One patient from each group was admitted overnight (table 3) .
Discussion
Various factors have been implicated in pain after arthroscopy and the effectiveness of intra-articular analgesia. These include preoperative pain scores, 7 duration 7 and type of surgery, 8 seniority of surgeon, 7 use of general or regional analgesia, 3 9 volume injected, 3 10 addition of adrenaline 3 and timing of intra-articular injection relative to tourniquet deflation. 10 These findings are inconsistent and more importantly details have not been recorded or are poorly matched between studies. Not all studies were performed as day-cases, 11 premedication and peroperative opioid analgesia varied widely and in some studies suxamethonium was used. 3 9 11 Pain assessment varied, with few studies assessing pain on movement, and techniques of statistical analysis of pain scores differed. This makes the large number of studies difficult to compare. In the design of this study we attempted to use best practice in performance and analysis.
We included a placebo group in this study as the efficacy of intra-articular bupivacaine is not proved; we gave modest doses of fentanyl in the peroperative period for ethical reasons. Pain scores were assessed at rest and on movement and were comparable with those reported in most similar studies.
The availability of analgesia on demand may lead to a converging of pain scores, as differences in pain are translated into differences in behaviour and analgesic consumption. In this study differences between groups in measures of pain (VAS and VRS at rest, on movement and disturbance by pain at night) and behaviour (mobilization) were not statistically significant. The only statistically significant difference between groups was for analgesic use. Patients in group Ten used significantly less oral analgesia in the first 24 h than those in the two other groups. Time to first analgesia was twice as long in group Ten than in the other groups; this was not significant. Some studies have found only small differences between analgesic requirements in intervention and placebo groups. In one study with no peroperative analgesia, 63% of patients in a placebo group required no analgesia in hospital and 29% used no analgesia at home. 12 The fact that some patients require negligible analgesia has led some to conclude that pain after arthroscopy is a poor model for testing efficacy of analgesics. 13 In this study 85% of our patients required analgesia at home and 25% were disturbed by pain on both of the first two nights after operation, while 15% took no analgesia at home. These findings do not suggest that pain after arthroscopy is insignificant but rather that it is variable.
Studies of intra-articular analgesia have revealed inconsistent findings, with local anaesthetics, particularly bupivacaine, found to be either ineffective 7 or effective only for short periods.
14 Intra-articular morphine has also been found to be ineffective, 3 6 10 to cause pain after injection 4 or to have a delayed onset of effect. 11 14 The combination of local anaesthetic and morphine has been found to provide rapid onset and prolonged analgesia 14 but also to be no more effective than morphine alone 10 or bupivacaine alone. 6 NSAID are effective when given parenterally after arthroscopy 1 and may improve recovery. 15 The main site of action is peripheral, reducing nociception, 16 with fewer spinal effects. 5 NSAID may also reduce pain by modifying the local inflammatory process. As the pain of arthroscopy arises in the joint, it is logical to use a peripherally acting drug at the site of injury. One can postulate that using the drug locally may produce greater efficacy and reduced side effects. The difference in analgesia provided by matched doses of i.v. or intra-articular tenoxicam has not been determined and as this study had no i.v. group it did not test this hypothesis.
This study is the first blinded controlled examination of the use of an intra-articular NSAID for postarthroscopy analgesia. The use of intra-articular ketorolac has been reported in three studies which claimed an analgesic effect equivalent to that of intra-articular local anaesthetic 17 18 and morphine. 19 These studies had no placebo group, used large doses (six times the current recommended parenteral dose) and in two studies pain scores were evaluated for only 2 h after operation. Diclofenac has also been used by the intra-articular route in an uncontrolled series of patients. 20 Good analgesia was reported but there have been reports of the injection causing both pain 19 and inflammation (personal communication, Ciba Pharmaceuticals).
Tenoxicam is an NSAID of the oxicam class with a prolonged elimination half-life. 21 It has a favourable side effect profile as it causes less gastrointestinal irritation than diclofenac SR, aspirin or indomethacin. 21 It has been used parenterally for knee arthroscopy 22 when it reduced pain in the first hour after operation. As the drug is water soluble and does not require a solubilizing agent, it is particularly suitable for intra-articular injection. Several NSAID have effects on animal and human cartilage (reduced chondrocyte biosynthesis and cartilage destruction) in vitro and in vivo that can be deleterious, 23 particularly to patients with osteoarthritis. These effects vary between different NSAID. 24 In contrast with other NSAID, tenoxicam may not suppress chondro-formative processes in human osteoarthritic cartilage (in vitro) 25 and may have beneficial effects. 26 Further, tenoxicam tends to be concentrated in the synovium rather than the cartilage. 27 While there may be some question as to whether or not all NSAID are safe for intra-articular injection we believe tenoxicam is safe. Despite this, for safety reasons we excluded patients with osteoarthritis.
The prospect of using carefully selected NSAID intra-articularly raises the possibility of providing intra-articular "balanced analgesia". One study compared intra-articular ketorolac with intraarticular morphine and the combination of both. 18 Arthroscopies were performed under bupivacaine local anaesthesia with sedation. The conclusions were that each drug provided equivalent analgesia with no benefit from combining the two; there was no placebo group. It is not known if the antiinflammatory effect of the NSAID interferes with peripheral opioid analgesia, which requires tissue inflammation for expression of peripheral opioid receptors. 3 
